AZ's Faslodex improves disease control

22 December 2008

New data show for the first time that high-dose treatment with AstraZeneca's Faslodex (fulvestrant) 500mg offers improved disease control compared with another AZ drug, the aromatase inhibitor Arimidex (anastrozole), when used as a first-line treatment for advanced hormone receptor-positive breast cancer.

Findings from the FIRST trial, a randomized, open-label, Phase II study in postmenopausal women with locally-advanced or metastatic disease, were presented by the Anglo-Swedish drug major at the 31st annual San Antonio Breast Cancer Symposium.

In the trial, women receiving fulvestrant 500mg experienced a clinical benefit rate (an established marker of disease response) of 72.5% compared with 67.0% for those given anastrozole (p=0.386) at a median follow-up of eight months. Although the study demonstrated a high level of clinical efficacy for both agents, the odds of achieving clinical benefit was 30% higher in women receiving fulvestrant 500mg (odds ratio 1.30 in favor of fulvestrant 500mg). In addition, those on fulvestrant 500mg had significantly prolonged time-to-disease progression, estimated to be 60% longer when compared with anastrozole (p<0.05).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight